 |
Journal articles
Feasibility of Dose Escalation in Patients With Intracranial Pediatric Ependymoma
Fatima Tensaouti
1, 2
Anne Ducassou
2
Leonor Chaltiel
2
Stéphanie Bolle
3, 4
Jean Louis Habrand
5, 6
Claire Alapetite
7
Bernard Coche-Dequeant
8
Valerie Bernier
9
Line Claude
10
Christian Carrie
10
Laetitia Padovani
11
Xavier Muracciole
11
Stephane Supiot
12
Aymeri Huchet
13
Julie Leseur
14
Christine Kerr
15
Grégorie Hangard
2
Albert Lisbona
12
Farid Goudjil
7
Régis Ferrand
2
Anne Laprie
1, 2, 16
Fatima Tensaouti 1, 2
Author
Anne Ducassou 2
Author
Leonor L. Chaltiel 2
Author
Stéphanie Bolle 3, 4
Author
Jean Louis Habrand 5, 6
Author
Claire Alapetite 7
Author
Bernard Coche-Dequeant 8
Author
Valerie Bernier 9
Author
Line Claude 10
Author
Christian Carrie 10
Author
Laetitia Padovani 11
Author
Xavier Muracciole 11
Author
Anne Laprie 1, 2, 16
Author
1
ToNIC - Toulouse Neuro Imaging Center (CHU PURPAN - Pavillon Baudot - Place du Dr Baylac 31024 TOULOUSE - Cedex 3 - France)
- UT3 - Université Toulouse III - Paul Sabatier (118 route de Narbonne - 31062 Toulouse - France)
- Université Fédérale Toulouse Midi-Pyrénées (41 Allée Jules Guesde, 31000 Toulouse - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1214 (101, rue de Tolbiac, 75013 Paris - France)
- Hôpital Purpan [Toulouse] (Place du Docteur Baylac
TSA 40031
31059 Toulouse cedex 9 - France)
- CHU Toulouse [Toulouse] (Hôtel-Dieu Saint Jacques 2, rue Viguerie TSA 80035 31059 Toulouse cedex 9 - France)
2
IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole (Av. Irène Joliot-Curie 31100 Toulouse - France)
- UT3 - Université Toulouse III - Paul Sabatier (118 route de Narbonne - 31062 Toulouse - France)
- Université Fédérale Toulouse Midi-Pyrénées (41 Allée Jules Guesde, 31000 Toulouse - France)
- CHU Toulouse [Toulouse] (Hôtel-Dieu Saint Jacques 2, rue Viguerie TSA 80035 31059 Toulouse cedex 9 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale (101, rue de Tolbiac, 75013 Paris - France)
3
IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France)
5
UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (3 avenue général Harris, 14000 Caen - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
- TCBN - Tumorothèque de Caen Basse-Normandie (3 avenue du Général Harris 14076 Caen cedex 5 - France)
- NU - Normandie Université (Esplanade de la Paix - CS 14032 - 14032 Caen Cedex 5 - France)
6
ABTE - Aliments Bioprocédés Toxicologie Environnements (Campus 2
Boulevard Maréchal Juin
14032 Caen cedex - France)
- UNICAEN - Université de Caen Normandie : EA4651 (Esplanade de la Paix - CS 14032 - 14032 CAEN Cedex 5 - France)
- NU - Normandie Université (Esplanade de la Paix - CS 14032 - 14032 Caen Cedex 5 - France)
- UNIROUEN - Université de Rouen Normandie : EA4651 (1, rue Thomas Becket 76821 Mont-Saint-Aignan Cedex - France)
- NU - Normandie Université (Esplanade de la Paix - CS 14032 - 14032 Caen Cedex 5 - France)
7
Institut Curie [Paris] ( 26 rue d'Ulm - 75248 Paris - France)
8
UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (3, rue Frédéric Combemale, 59020 Lille - France)
- Université Lille Nord de France (COMUE) (365 bis, rue Jules Guesde BP 50458 - 59658 Villeneuve d’Ascq Cedex - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
9
UNICANCER/ICL - Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (6 avenue de Bourgogne, 54519 Vandoeuvre les Nancy - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
10
Centre Léon Bérard [Lyon] (28, rue Laennec 69373 LYON Cedex 08 - France)
11
TIMONE - Hôpital de la Timone [CHU - APHM] (France)
12
UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes] (15, rue André Boquel - 49055 Angers cedex 02 - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
13
CHU Bordeaux [Bordeaux] (place Amélie Raba Léon
33076 BORDEAUX CEDEX - France)
14
CRLCC - Centre Eugène Marquis (Avenue Bataille Flandres-Dunkerque 35042 RENNES CEDEX - France)
15
ICM - Institut du Cancer de Montpellier (ICM
208, Avenue des Apothicaires
Parc Euromédecine
34298 Montpellier Cedex 5 - France)
16
UT3 - Université Toulouse III - Paul Sabatier (118 route de Narbonne - 31062 Toulouse - France)
- Université Fédérale Toulouse Midi-Pyrénées (41 Allée Jules Guesde, 31000 Toulouse - France)
Abstract : Background and purpose: Pediatric ependymoma carries a dismal prognosis, mainly owing to local relapse within RT fields. The current prospective European approach is to increase the radiation dose with a sequential hypofractionated stereotactic boost. In this study, we assessed the possibility of using a simultaneous integrated boost (SIB), comparing VMAT vs. IMPT dose delivery.
Material and methods: The cohort included 101 patients. The dose to planning target volume (PTV59.4) was 59.4/1.8 Gy, and the dose to SIB volume (PTV67.6) was 67.6/2.05 Gy. Gross tumor volume (GTV) was defined as the tumor bed plus residual tumor, clinical target volume (CTV59.4) was GTV + 5 mm, and PTV59.4 was CTV59.4 + 3 mm. PTV67.6 was GTV+ 3 mm. After treatment plan optimization, quality indices and doses to target volume and organs at risk (OARs) were extracted and compared with the standard radiation doses that were actually delivered (median = 59.4 Gy [50.4 59.4]).
Results: In most cases, the proton treatment resulted in higher quality indices (p < 0.001). Compared with the doses that were initially delivered, mean, and maximum doses to some OARs were no higher with SIB VMAT, and significantly lower with protons (p < 0.001). In the case of posterior fossa tumor, there was a lower dose to the brainstem with protons, in terms of V59 Gy, mean, and near-maximum (D2%) doses.
Conclusion: Dose escalation with intensity-modulated proton or photon SIB is feasible in some patients. This approach could be considered for children with unresectable residue or post-operative FLAIR abnormalities, particularly if they have supratentorial tumors. It should not be considered for infratentorial tumors encasing the brainstem or extending to the medulla.
Document type :
Journal articles
Complete list of metadata
https://hal-normandie-univ.archives-ouvertes.fr/hal-02478956
Contributor : Carine Laurent Connect in order to contact the contributor
Submitted on : Wednesday, July 1, 2020 - 9:20:38 AM
Last modification on : Tuesday, October 19, 2021 - 11:34:54 PM
Long-term archiving on: : Wednesday, September 23, 2020 - 2:24:25 PM
Contributor : Carine Laurent Connect in order to contact the contributor
Submitted on : Wednesday, July 1, 2020 - 9:20:38 AM
Last modification on : Tuesday, October 19, 2021 - 11:34:54 PM
Long-term archiving on: : Wednesday, September 23, 2020 - 2:24:25 PM
File
fonc-09-00531.pdf
Publisher files allowed on an open archive
Licence
Distributed under a Creative Commons Attribution 4.0 International License
Identifiers
- HAL Id : hal-02478956, version 1
- DOI : 10.3389/fonc.2019.00531
- PUBMED : 31293971
Collections
COMUE-NORMANDIE | UNICAEN | ABTE | ICO | VAUTRIN | LAMBRET | BACLESSE | FNCLCC | UNIV-TLSE3 | UNIROUEN | CURIE | INSERM | PSL | IGR | POLITIQUES-PUBLIQUES
Citation
Fatima Tensaouti, Anne Ducassou, Leonor Chaltiel, Stéphanie Bolle, Jean Louis Habrand, et al.. Feasibility of Dose Escalation in Patients With Intracranial Pediatric Ependymoma. Frontiers in Oncology, Frontiers, 2019, 9, pp.531. ⟨10.3389/fonc.2019.00531⟩. ⟨hal-02478956⟩
Metrics
Record views
320
Files downloads
